Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (21-30 of 192) with videos related to

Pageof 20
Sort By:
Clinics and Research in Hepatology and Gastroenterology|August 21, 2022
Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature reviewCindy Neuzillet, David Malka, Astrid Lièvre, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 24, 2021
Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitorsMarine Valery, Francesco Facchinetti, David Malka, et al.
Current Opinion in Oncology|June 10, 2004
Biliary tract neoplasms: update 2003David Malka, Valérie Boige, Clarisse Dromain, et al.
Expert Opinion on Investigational Drugs|March 1, 2021
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancersAlice Boilève, Loïc Verlingue, Antoine Hollebecque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatmentGabriel Rahmi, David Malka, Gorana Tomasic, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2020
Immune scores in colorectal cancer: Where are we?David Malka, Astrid Lièvre, Thierry André, et al.
The Lancet. Oncology|December 2, 2006
Splenic infarction and bevacizumabDavid Malka, Marc Van den Eynde, Valérie Boige, et al.
Cancers|April 3, 2021
Immunotherapy in Advanced Biliary Tract CancersAlice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Sentinel lymph node sampling and analysis in colon cancer: what is the question?Marc Pocard, Marc Van den Eynde, Diane Goere, et al.
Pageof 20

Showing results (21-30 of 192) with videos related to

Sort By:
Pageof 20
Clinics and Research in Hepatology and Gastroenterology|August 21, 2022
Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature reviewCindy Neuzillet, David Malka, Astrid Lièvre, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 24, 2021
Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitorsMarine Valery, Francesco Facchinetti, David Malka, et al.
Current Opinion in Oncology|June 10, 2004
Biliary tract neoplasms: update 2003David Malka, Valérie Boige, Clarisse Dromain, et al.
Expert Opinion on Investigational Drugs|March 1, 2021
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancersAlice Boilève, Loïc Verlingue, Antoine Hollebecque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatmentGabriel Rahmi, David Malka, Gorana Tomasic, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2020
Immune scores in colorectal cancer: Where are we?David Malka, Astrid Lièvre, Thierry André, et al.
The Lancet. Oncology|December 2, 2006
Splenic infarction and bevacizumabDavid Malka, Marc Van den Eynde, Valérie Boige, et al.
Cancers|April 3, 2021
Immunotherapy in Advanced Biliary Tract CancersAlice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Sentinel lymph node sampling and analysis in colon cancer: what is the question?Marc Pocard, Marc Van den Eynde, Diane Goere, et al.
Pageof 20